|
Price: $141.7950
$3.30 
2.379%
|
| Day's High:
| $138.8
| Week Perf:
| 2.25 %
|
| Day's Low: |
$ 138.09 |
30 Day Perf: |
0.44 % |
| Volume (M): |
119 |
52 Wk High: |
$ 168.11 |
| Volume (M$): |
$ 16,416 |
52 Wk Avg: |
$149.00 |
| Open: |
$138.02 |
52 Wk Low: |
$130.96 |
|
|
| Market Capitalization (Millions $) |
251,119 |
| Shares
Outstanding (Millions) |
1,771 |
| Employees |
50,000 |
| Revenues (TTM) (Millions $) |
55,138 |
| Net Income (TTM) (Millions $) |
6,521 |
| Cash Flow (TTM) (Millions $) |
1,455 |
| Capital Exp. (TTM) (Millions $) |
785 |
Abbvie Inc
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following
separation from Abbott. The company’s mission is to use its expertise, dedicated
people and unique approach to innovation to develop and market advanced therapies
that address some of the world’s most complex and serious diseases.
Company Address: 1 North Waukegan Road North Chicago 60064 IL
Company Phone Number: 932-7900 Stock Exchange / Ticker: NYSE ABBV
| ABBV is expected to report next financial results on February 16, 2024. |
|
|
|
|
Customers Net Income grew by |
ABBV's Customers Net Profit Margin grew to |
4.14 % |
4.02 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Enveric Biosciences Inc
Enveric Biosciences Inc (ENVB), a biotechnology company specializing in the development of novel neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders, recently released its financial results for the third quarter of 2023. While the figures indicate an operating shortfall and net loss, there are promising signs that suggest a positive trajectory for the company's future.
Operating Shortfall Progress:
During Q3 2023, ENVB reported an operating shortfall of $-3.448395 million. However, when comparing this to the same period in 2022, where the operating shortfall was $-5.656849 million, it is evident that the company has made significant strides in improving its financial position. This improvement acts as a crucial sign that ENVB's business model is gaining traction.
|
|
Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc, a renowned biopharmaceutical company, recently released its financial results for the third quarter of 2023. While the revenue figures may seem low at $0.016 million, it is crucial to understand the context behind this decline. Despite the net deficit of $-5.982 million, larger than the previous year, strategic factors and upcoming events indicate that Cyclacel Pharmaceuticals Inc may present a significant opportunity for investors.
Revenue Insights and Future Expectations
Cyclacel Pharmaceuticals Inc's third-quarter revenue of $0.016 million reflects a temporary setback. However, it is essential to note that pharmaceutical companies often face fluctuations in revenue due to various factors such as drug development timelines, regulatory approvals, and clinical trials. These figures do not accurately reflect the long-term growth potential and overall strength of the company.
|
|
Arrowhead Pharmaceuticals Inc
Financial News Report: Arrowhead Pharmaceuticals Inc Announces Q4 2023 Earnings
Arrowhead Pharmaceuticals Inc has reported its financial results for the fourth quarter of 2023 earnings season, revealing a significant increase in its loss per share. The company recorded a loss of $-1.02 per share, compared to $-0.81 per share in the same quarter the previous year, and a growth in loss from $-0.96 per share from the previous quarter.
Additionally, the company's revenue for the quarter declined by -49.02% to $16.10 million, down from $31.58 million in the same quarter a year before. However, sequentially, the revenue grew by 1.719% from $15.83 million.
|
|
Lixte Biotechnology Holdings Inc
Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.
|
|
Earth Science Tech Inc
Earth Science Tech Inc, a leading company in the science and wellness industry, has recently released its financial results for the fiscal interval closing September 30, 2023. The results indicate a significant improvement in revenue, earnings, and profit margins. Additionally, the company's stock performance has been impressive, reflecting strong investor confidence. This article will outline the key facts from the financial results and provide an overview of the context surrounding Earth Science Tech Inc's recent achievements.
Financial Results:
1. Revenue: Earth Science Tech Inc achieved revenue of $1.92772 million in the fiscal interval closing September 30, 2023. This represents a substantial increase compared to the same quarter the previous year.
|
| Per Share |
Current |
| Earnings (TTM) |
3.66 $ |
| Revenues (TTM) |
31.13 $
|
| Cash Flow (TTM) |
0.82 $ |
| Cash |
7.5 $
|
| Book Value |
6.85 $
|
| Dividend (TTM) |
5.87 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
3.66 $
|
| Revenues (TTM) |
31.13 $ |
| Cash Flow (TTM) |
0.82 $ |
| Cash |
7.5 $
|
| Book Value |
6.85 $ |
| Dividend (TTM) |
5.87 $ |
|
|
| |
| HUMIRA |
|
Segment |
|
 |
of total Revenue |
| Kaletra |
|
Segment |
|
|
of total Revenue |
| AndroGel |
|
Segment |
|
|
of total Revenue |
| Lupron |
|
Segment |
|
|
of total Revenue |
| Synthroid |
|
Segment |
|
|
of total Revenue |
| Other |
|
Segment |
|
|
of total Revenue |
| Synagis |
|
Segment |
|
|
of total Revenue |
| Sevoflurane |
|
Segment |
|
|
of total Revenue |
| Creon |
|
Segment |
|
|
of total Revenue |
| VIEKIRA |
|
Segment |
|
|
of total Revenue |
| Dyslipidemia products |
|
Segment |
|
|
of total Revenue |
| |
|
|
1.48% 